We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-14.23%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.99B
AUM Growth
-$1.5B
Cap. Flow
-$524M
Cap. Flow %
-10.5%
Top 10 Hldgs %
44.72%
Holding
159
New
13
Increased
22
Reduced
36
Closed
24

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$47.6M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$33.3M
3
NVRO
NEVRO CORP.
NVRO
+$32.7M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$32.1M
5
PEN icon
Penumbra
PEN
+$31.9M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$46.5M
4
KOD icon
Kodiak Sciences
KOD
+$44.1M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$37.1M

Sector Composition

Rank Sector Weight
1 Healthcare 86.45%
2 Miscellaneous 12.62%
3 Financials 0.77%
4 Industrials 0.12%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLGCW
126
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$235K ﹤0.01%
110,000
– –
SRZN icon
127
Surrozen
SRZN
$209M
$234K ﹤0.01%
5,182
-22,381
-81% -$1.11M
UTRS
128
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$226K ﹤0.01%
2,513
-1,875
-43% -$191K
EQRXW
129
DELISTED
EQRx, Inc. Warrant
EQRXW
$218K ﹤0.01%
250,000
– –
CMAXW
130
DELISTED
CareMax, Inc. Warrant
CMAXW
$114K ﹤0.01%
60,000
– –
SRZNW
131
DELISTED
Surrozen Inc Warrant
SRZNW
$42K ﹤0.01%
166,666
– –
ADPT icon
132
Adaptive Biotechnologies
ADPT
$4.26B
– –
-352,804
Closed -$9.9M
AXSM icon
133
Axsome Therapeutics
AXSM
$10.7B
– –
-80,420
Closed -$3.04M
BCAB
134
DELISTED
BIOATLA INC
BCAB
– –
-13,224
Closed -$13M
BIIB icon
135
Biogen
BIIB
$31.9B
– –
-48,600
Closed -$11.7M
BMRN icon
136
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-1,180,000
Closed -$104M
CLDX icon
137
Celldex Therapeutics
CLDX
$3.02B
– –
-229,807
Closed -$8.88M
HRMY icon
138
Harmony Biosciences
HRMY
$2.46B
– –
-239,258
Closed -$10.2M
IMCR icon
139
Immunocore
IMCR
$1.64B
– –
-360,000
Closed -$12.3M
ITOS
140
DELISTED
iTeos Therapeutics
ITOS
– –
-20,000
Closed -$931K
KOD icon
141
Kodiak Sciences
KOD
$2.07B
– –
-520,152
Closed -$44.1M
KYMR icon
142
Kymera Therapeutics
KYMR
$9.41B
– –
-155,000
Closed -$9.84M
PHVS icon
143
Pharvaris
PHVS
$2.67B
– –
-27,000
Closed -$389K
PMVP icon
144
PMV Pharmaceuticals
PMVP
$72.7M
– –
-125,000
Closed -$2.89M
FLNA
145
PUT
Filana Therapeutics
FLNA
$33.6M
– –
-300,000
Closed -$13.1M
UTHR icon
146
United Therapeutics
UTHR
$21.5B
– –
-94,064
Closed -$20.3M
VTRS icon
147
Viatris
VTRS
$19.1B
– –
-1,004,419
Closed -$13.6M
YARW
148
Yarrow Bioscience
YARW
$68.1M
– –
-2,420
Closed -$2.22M
ACHL
149
DELISTED
Achilles Therapeutics
ACHL
– –
-755,375
Closed -$3.78M
TBIO
150
DELISTED
Telesis Bio, Inc. Common Stock
TBIO
– –
-23,611
Closed -$4.59M
3 4 5
6
7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Perceptive Advisors held 159 positions worth $4.99B, down 23% from $6.49B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $524M in Q1 2022, closing 24 positions and reducing 36 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Perceptive Advisors opened a new position in CinCor Pharma, Inc. Common Stock worth $40.7M.

  • Perceptive Advisors's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 2,319,117 shares worth $40.7M.
  • Perceptive Advisors added most to NEVRO CORP. in Q1 2022, an estimated $32.7M increase.
  • Perceptive Advisors's biggest Q1 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $92.4M.
  • Perceptive Advisors fully exited BioMarin Pharmaceuticals in Q1 2022, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $4.99B portfolio in Q1 2022.
  • Perceptive Advisors opened 13 new positions and closed 24 in Q1 2022.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $4.99B.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.